Search
for
Sort by
Research
330-360 / 1000+ resultsresearch Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research [[Translated article]]RF- Mesotherapy with Bicalutamide: A Novel Alternative for Androgenetic Alopecia
RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.
research Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising
Social media can help compare the effectiveness and safety of new arthritis medications.
research Leflunomide
Leflunomide is effective for rheumatoid arthritis but has significant side effects.
research Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild‐to‐moderate alopecia areata: A multicenter, prospective, randomized, controlled, investigator‐blinded trial
Betamethasone valerate foam is more effective and safe for treating mild-to-moderate alopecia areata than betamethasone dipropionate lotion.
research 151 High effectiveness of tildrakizumab over 52 weeks in patients with or without nail psoriasis: results from the phase IV POSITIVE Austrian subset
Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
research 440 Squaric acid dibutylester, used in alopecia areata immunotherapy, promotes innate immune-driven hair growth with CD206+ macrophage accumulation in the dermis
Squaric acid dibutylester helps hair growth by increasing certain immune cells in the skin.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research A case of atopic dermatitis with self‐healing acute diffuse and total alopecia during nemolizumab treatment
research Immunomodulatory Potential of a Bibenzyl-dihydrophenanthrene Derivative Isolated from Calanthe cardioglossa
Calancardin B may help reduce inflammation in immune cells.
research A Single Subcutaneous Dose of BMD-1141 Stimulates Hair Regrowth Comparable to Daily, High-Dose Ruxolitinib in a Mouse Model of Alopecia Areata.
BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.
research Agreement Between Patient and Physician Assessment of Eyebrow and Eyelash Hair Loss in Two Phase 3 Trials Evaluating Baricitinib in Patients with Severe Alopecia Areata
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index
Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research 43927 The Impact of Treatment with Guselkumab on Skin-related Quality of Life in Male and Female Patients with Moderate to Severe Psoriasis: Results from the VOYAGE 1 and 2 Trials
Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.
research Bimatoprost for the treatment of female androgenetic alopecia—A case report
research 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
Baricitinib was effective in treating both early and late onset alopecia areata.
research Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo
3D imaging effectively tracks skin changes in vitiligo treatment.
research Mechanism of action of bolandiol (19-nortestosterone-3β,17β-diol), a unique anabolic steroid with androgenic, estrogenic, and progestational activities
Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.
research P79: Efficacy of baricitinib in adults with alopecia areata: patients’ perspectives on hair regrowth from two phase III randomized controlled trials (BRAVE‐AA1 and BRAVE‐AA2)
Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.
research From joint pains to hair gains: baricitinib’s double duty for rheumatoid arthritis and alopecia areata
Baricitinib effectively treats both rheumatoid arthritis and alopecia areata.
research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research 808 Lichen planus single cell and spatial profiling of cutaneous lichen planus treated with baricitinib
research Perifolliculitis capitis abscedens et suffodiens treatment with tumor necrosis factor inhibitors and baricitinib: A case report and literature review
A 15-year-old boy's severe scalp condition improved significantly with adalimumab and baricitinib treatment.
research Biologic: A Double Edged Sword - A Case of Etanercept Induced Alopecia Areata in a Patient with Psoriasis Vulgaris
Etanercept, a psoriasis treatment, caused hair loss in a patient.
research Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism
Low-dose Buserelin effectively reduces hirsutism with minimal side effects.
research Characterizing Lipid Changes and Use of Lipid-Lowering Medications in Patients With Alopecia Areata Treated With Baricitinib: Integrated Results From the BRAVE-AA1 and -AA2 Clinical Trials
Baricitinib slightly increased cholesterol levels in alopecia areata patients, but these changes were manageable.